SCA
WST icon

Snowden Capital Advisors’s West Pharmaceutical WST Stock Holding History

Snowden Capital Advisors’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312K Sell
869
-70
-7% -$21.4K 0.01% 1055
2026
Q1 		$235K Buy
939
+41
+5% +$10.2K 0.01% 1132
2025
Q4 		$247K Sell
898
-92
-9% -$25.2K 0.01% 1126
2025
Q3 		$260K Sell
990
-18
-2% -$4.38K 0.01% 1080
2025
Q2 		$221K Buy
1,008
+32
+3% +$6.84K 0.01% 1136
2025
Q1 		$219K Buy
976
+129
+15% +$35.6K 0.01% 1124
2024
Q4 		$278K Sell
847
-22
-3% -$6.92K 0.01% 1023
2024
Q3 		$261K Sell
869
-68
-7% -$20.8K 0.01% 1070
2024
Q2 		$309K Sell
937
-8,232
-90% -$2.91M 0.01% 959
2024
Q1 		$3.63M Buy
9,169
+1,510
+20% +$559K 0.11% 222
2023
Q4 		$2.7M Sell
7,659
-1,623
-17% -$574K 0.1% 236
2023
Q3 		$3.48M Sell
9,282
-30
-0.3% -$11.6K 0.15% 195
2023
Q2 		$3.56M Buy
9,312
+8,145
+698% +$2.91M 0.13% 209
2023
Q1 		$404K Buy
1,167
+112
+11% +$32.7K 0.02% 823
2022
Q4 		$248K Sell
1,055
-453
-30% -$107K 0.01% 996
2022
Q3 		$371K Sell
1,508
-189
-11% -$57.6K 0.02% 791
2022
Q2 		$513K Sell
1,697
-34
-2% -$11.1K 0.02% 619
2022
Q1 		$711K Buy
1,731
+515
+42% +$202K 0.03% 524
2021
Q4 		$570K Sell
1,216
-381
-24% -$164K 0.03% 432
2021
Q3 		$678K Sell
1,597
-35
-2% -$14.8K 0.03% 456
2021
Q2 		$586K Buy
1,632
+492
+43% +$163K 0.03% 500
2021
Q1 		$321K Buy
+1,140
New +$326K 0.02% 605
2020
Q4 		– Sell
-959
Closed -$264K – 688
2020
Q3 		$264K Buy
+959
New +$254K 0.02% 493

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Snowden Capital Advisors's WST Position: Q2 2026 in Review

Snowden Capital Advisors reduced its West Pharmaceutical (WST) stake by 7.5% in Q2 2026, selling an estimated $21.4K and leaving 869 shares worth $312K. The position accounts for 0.01% of the portfolio, ranked #1055.

Snowden Capital Advisors first reported a position in WST in Q3 2020 and has held it in 23 quarters since. The position peaked at $3.63M in Q1 2024. 830 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Snowden Capital Advisors held 869 shares of West Pharmaceutical worth $312K as of Q2 2026.
  • Snowden Capital Advisors sold 70 West Pharmaceutical shares in Q2 2026, an estimated $21.4K.
  • West Pharmaceutical made up 0.01% of Snowden Capital Advisors's portfolio in Q2 2026, its #1055 holding.
  • Snowden Capital Advisors first reported a position in West Pharmaceutical in Q3 2020 and has held it in 23 quarters since.
  • Snowden Capital Advisors's West Pharmaceutical position peaked at $3.63M in Q1 2024.
  • 830 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.